NCT02002325 - THrombolysis for Acute Wake-up and Unclear-onset Strokes With Alteplase at 0.6 mg/kg Trial (THAWS) | Biotech Hunter

Enrollment

300

Participants

Timeline

Start Date

May 31, 2014

Primary Completion Date

December 31, 2019

Study Completion Date

March 31, 2020

Conditions

Stroke

Interventions

DRUG

Tissue-type plasminogen activator (alteplase)

Intravenous tissue-type plasminogen activator (alteplase) 0.6mg/kg body-weight up to a maximum of 60 mg, 10% as bolus, 90% over 1 hour as infusion (plus other standard treatment if needed)

OTHER

Standard care

Standard treatment for acute stroke without intravenous alteplase.

Trial Locations (1)

565-8565

National Cerebral and Cardiovascular Center, Suita